Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is involved in developmental therapeutics research in leukemia. Over the past years he has assisted in developing chemotherapeutic and biologic agents in leukemias. These include: Hyper CVAD-ofatumumab regimen in ALL; clofarabine in myeloid malignancies; hypomethylating agents in AML and MDS; Tyrosine kinase therapy in CML; and triple therapy in AML. This research provided insight into the biology of leukemias. He has addressed the question of resistance to tyrosine kinase inhibitors and analyzed the outcome. This has clinical significance, establishing new milestones leading to personalized therapy, and consequences at the scientific and financial levels. He was also associated with frontline studies of nilotinib and dasatinib which resulted in FDA approval for frontline CML therapy in 2010. This served as a rationale for the first study in the world randomizing such patients to either 5-azacitidine or decitabine. Identifying patients and applying earlier intervention may significantly improve their prognosis. He is leading our efforts to test triple therapy in AML (nucleoside analogs + anthracyclines + cytarabine). The interim results from this randomized trial show a significant improvement. He is currently investigating the benefit of adding humanized monoclonal antibody for the treatment of patients with ALL and collaborating in the development of monoclonal antibody studies in adult ALL. Finally, he has authored or co-authored hundreds of peer reviewed medical publications and have served on editorial boards of several scientific journals.